Company: LCTX
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0000950170-25-070378
Chunk: 4

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Item 2
Chunk 4
---
 as RG6501) is a suspension of human allogeneic retinal pigmented epithelial (“RPE”) cells and is currently being evaluated in a Phase 2a multicenter clinical trial in patients with GA secondary to AMD which is referred to as the “GAlette Study”. OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. Under the terms of the Collaboration and License Agreement we entered into with Roche in